Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative

Cécile Colavolpe; Eric Guedj; Serge Cammilleri; David Taïeb; Olivier Mundler; Carole Coze

doi:10.1002/pbc.21594

Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative

Pediatr Blood Cancer. 2008 Dec;51(6):828-31. doi: 10.1002/pbc.21594.

Authors

Cécile Colavolpe¹, Eric Guedj, Serge Cammilleri, David Taïeb, Olivier Mundler, Carole Coze

Affiliation

¹ Department of Nuclear Medicine, University Hospital Centre, Timone, Marseille, France. [email protected]

PMID: 18680162
DOI: 10.1002/pbc.21594

Abstract

We report on the case of a 10-month-old female infant with a metastatic neuroblastoma which became MIBG-negative at time of relapse. We discuss the different hypothesis associated with this particular outcome, and the potential utility of FDG-PET as an alternative to follow up the residual disease at this stage.

Publication types

Case Reports

MeSH terms

3-Iodobenzylguanidine / metabolism*
Female
Fluorodeoxyglucose F18* / metabolism
Follow-Up Studies
Humans
Infant
Neoplasm Recurrence, Local / diagnostic imaging*
Neoplasm Recurrence, Local / pathology
Neoplasm, Residual / diagnostic imaging
Neoplasm, Residual / pathology
Neuroblastoma / diagnostic imaging*
Neuroblastoma / secondary
Positron-Emission Tomography
Prognosis
Radiopharmaceuticals
Tomography, X-Ray Computed
Treatment Outcome

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18
3-Iodobenzylguanidine